JP6009532B2 - タンパク質複合体及び該タンパク質複合体を含むワクチン組成物の生産方法 - Google Patents

タンパク質複合体及び該タンパク質複合体を含むワクチン組成物の生産方法 Download PDF

Info

Publication number
JP6009532B2
JP6009532B2 JP2014500473A JP2014500473A JP6009532B2 JP 6009532 B2 JP6009532 B2 JP 6009532B2 JP 2014500473 A JP2014500473 A JP 2014500473A JP 2014500473 A JP2014500473 A JP 2014500473A JP 6009532 B2 JP6009532 B2 JP 6009532B2
Authority
JP
Japan
Prior art keywords
stress
cells
heat shock
cell
protein complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014500473A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014510093A5 (enExample
JP2014510093A (ja
Inventor
コラコ カミロ
コラコ カミロ
マケンティー イアン
マケンティー イアン
Original Assignee
イミュノバイオロジー リミテッド
イミュノバイオロジー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミュノバイオロジー リミテッド, イミュノバイオロジー リミテッド filed Critical イミュノバイオロジー リミテッド
Publication of JP2014510093A publication Critical patent/JP2014510093A/ja
Publication of JP2014510093A5 publication Critical patent/JP2014510093A5/ja
Application granted granted Critical
Publication of JP6009532B2 publication Critical patent/JP6009532B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001176—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2014500473A 2011-03-23 2012-03-23 タンパク質複合体及び該タンパク質複合体を含むワクチン組成物の生産方法 Active JP6009532B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1104897.2A GB201104897D0 (en) 2011-03-23 2011-03-23 Method for the production of protein complexes and vaccine compositions comprising the same
GB1104897.2 2011-03-23
PCT/GB2012/050650 WO2012127248A1 (en) 2011-03-23 2012-03-23 Method for the production of protein complexes and vaccine compositions comprising the same

Publications (3)

Publication Number Publication Date
JP2014510093A JP2014510093A (ja) 2014-04-24
JP2014510093A5 JP2014510093A5 (enExample) 2015-05-07
JP6009532B2 true JP6009532B2 (ja) 2016-10-19

Family

ID=44013038

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014500473A Active JP6009532B2 (ja) 2011-03-23 2012-03-23 タンパク質複合体及び該タンパク質複合体を含むワクチン組成物の生産方法

Country Status (9)

Country Link
US (2) US10240179B2 (enExample)
EP (1) EP2688589B1 (enExample)
JP (1) JP6009532B2 (enExample)
CN (1) CN103458923A (enExample)
AU (2) AU2012232878A1 (enExample)
BR (1) BR112013024229A2 (enExample)
CA (1) CA2829678C (enExample)
GB (1) GB201104897D0 (enExample)
WO (1) WO2012127248A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5081243B2 (ja) * 2006-08-17 2012-11-28 ザ ユーエービー リサーチ ファウンデーション 肺炎球菌抗原を被検体における肺炎球菌性肺炎の指標とする方法
GB201104897D0 (en) * 2011-03-23 2011-05-04 Immunobiology Ltd Method for the production of protein complexes and vaccine compositions comprising the same
CA2874091C (en) * 2012-03-22 2023-09-26 Avita Medical Ltd. Method for preparing cell suspension comprising undifferentiated/progenitor cells and/or differentiated cells
CN108379553A (zh) * 2018-05-28 2018-08-10 上海市第人民医院 热休克蛋白20在氧化应激损伤疾病中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2189992A (en) * 1991-06-03 1993-01-08 Arch Development Corporation Methods and compositions of genetic stress response systems
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
GB9818133D0 (en) 1998-08-19 1998-10-14 Quadrant Holdings Cambridge Vaccine
US6495360B1 (en) 1999-05-28 2002-12-17 Photogen, Inc. Method for enhanced protein stabilization and for production of cell lines useful for production of such stabilized proteins
GB9919734D0 (en) * 1999-08-19 1999-10-20 Colaco Camilo Vaccines from infectious agents
GB9919733D0 (en) 1999-08-19 1999-10-20 Colaco Camilo Vaccines against intracellular pathogens
WO2001026432A1 (fr) 1999-10-01 2001-04-12 Seiko Epson Corporation Plaquette imprimee, dispositif a semi-conducteur et son procede de fabrication, ses essais et sa mise en boitier, et circuit integre et equipement electronique
GB0004547D0 (en) * 2000-02-23 2000-04-19 Immunobiology Ltd Screening method for novel vaccine candidates and compositions obtained thereby
GB0021757D0 (en) 2000-09-04 2000-10-18 Colaco Camilo Vaccine against microbial pathogens
WO2002028407A1 (en) 2000-09-29 2002-04-11 University Of Connecticut Health Center Methods of recovering heat shock proteins and complexes thereof
EP2300821A1 (en) * 2008-06-03 2011-03-30 Bin Zhang Screening methods for heat-shock response modulators
GB0816242D0 (en) 2008-09-05 2008-10-15 Immunobiology Ltd Method of purifying protien complexes
GB0910591D0 (en) * 2009-06-19 2009-07-29 Immunobiology Ltd Method for the purification of protein complexes
GB0916557D0 (en) 2009-09-21 2009-10-28 Health Prot Agency Commensal neisserial stress protein complexes
GB201104897D0 (en) * 2011-03-23 2011-05-04 Immunobiology Ltd Method for the production of protein complexes and vaccine compositions comprising the same

Also Published As

Publication number Publication date
US10240179B2 (en) 2019-03-26
US20140017274A1 (en) 2014-01-16
AU2017203173B2 (en) 2019-07-11
EP2688589A1 (en) 2014-01-29
US20190241923A1 (en) 2019-08-08
AU2012232878A1 (en) 2013-09-26
BR112013024229A2 (pt) 2016-12-20
CA2829678C (en) 2019-07-09
CN103458923A (zh) 2013-12-18
AU2017203173A1 (en) 2017-07-27
JP2014510093A (ja) 2014-04-24
CA2829678A1 (en) 2012-09-27
WO2012127248A1 (en) 2012-09-27
US10669563B2 (en) 2020-06-02
GB201104897D0 (en) 2011-05-04
EP2688589B1 (en) 2017-05-17

Similar Documents

Publication Publication Date Title
US10669563B2 (en) Method for the production of protein complexes and vaccine compositions comprising the same
CN103304670B (zh) 结核分枝杆菌特异性融合蛋白疫苗ab及其制备和应用
JP2009510169A (ja) 細菌抗原送達系を用いた免疫応答を刺激するための方法
US20110229503A1 (en) Vaccination against malignant melanoma using bcg and/or vaccinia
KR102148413B1 (ko) 이종 폴리펩티드를 포함하는 ＣｙａＡ에 기초한 키메라 단백질 및 면역 반응의 유도에 있어서의 그의 용도
US8784830B2 (en) Antigen peptide and use thereof
CN112203683A (zh) 作为佐剂的假鼻疽伯克霍尔德氏菌复合外膜囊泡
JP7445897B2 (ja) 細胞性免疫を誘導する経鼻ワクチン
ES2336417T3 (es) Proteinas del estres de patogenos extracelulares como vacunas contra agentes infecciosos.
AU2014336204B2 (en) Therapeutic cancer vaccine based on stress proteins rendered immunogenic
JP2010521965A (ja) スタフィロコッカス・エピデルミディス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓｅｐｉｄｅｒｍｉｄｉｓ）に対する防御免疫応答を誘発するポリペプチド
WO2009095518A1 (es) Protección heteróloga contra pasteurella multocida proporcionada por células de p. multocida fur y sus extractos proteicos de membrana externa
Romano et al. A Structural View at Vaccine Development against M. tuberculosis. Cells 2023, 12, 317
JP6039648B2 (ja) 併用ワクチン
RU2796973C2 (ru) Интраназальная вакцина, индуцирующая клеточно-опосредованный иммунитет
Gaspari Application of prime-boost as a novel vaccination strategy against microbial pathogens
WO2017163181A1 (pt) Composição vacinal contra as leishmanioses tegumentar e visceral, e uso
JP2015214493A (ja) エルシニア症ワクチン
BRPI0705676A2 (pt) uso do imunomodulador plasmidial expressando uma proteìna de estresse micobacteriana para o controle de micoses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160520

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160823

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160914

R150 Certificate of patent or registration of utility model

Ref document number: 6009532

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250